|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oversikt over luftvegsprøver, Mikrobiologisk
avdeling, HUS. |
2020-2021 |
|
|
Inneliggjande pasientar |
Veke 21-32 |
|
Veke 21-31 |
|
Veke 21-30 |
|
Veke 21-29 |
|
|
Totalt |
Påvist |
|
Totalt |
Påvist |
|
Totalt |
Påvist |
|
Totalt |
Påvist |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bordetella pertussis |
123 |
<5 |
|
|
106 |
<5 |
|
|
113 |
<5 |
|
|
109 |
<5 |
|
|
|
Bordetella parapertussis |
123 |
<5 |
|
|
106 |
<5 |
|
|
113 |
<5 |
|
|
109 |
<5 |
|
|
|
Mycoplasma pneumoniae |
123 |
<5 |
|
|
106 |
<5 |
|
|
113 |
<5 |
|
|
109 |
<5 |
|
|
|
Chlamydia pneumoniae |
123 |
<5 |
|
|
106 |
<5 |
|
|
113 |
<5 |
|
|
109 |
<5 |
|
|
|
Influensavirus A |
437 |
<5 |
|
|
352 |
<5 |
|
|
388 |
<5 |
|
|
306 |
<5 |
|
|
|
Influensavirus B |
437 |
<5 |
|
|
352 |
<5 |
|
|
388 |
<5 |
|
|
306 |
<5 |
|
|
|
Parainfluensavirus 1 |
123 |
<5 |
|
|
106 |
<5 |
|
|
113 |
<5 |
|
|
109 |
<5 |
|
|
|
Parainfluensavirus 2 |
123 |
<5 |
|
|
106 |
<5 |
|
|
113 |
<5 |
|
|
109 |
<5 |
|
|
|
Parainfluensavirus 3 |
123 |
<5 |
|
|
106 |
<5 |
|
|
113 |
<5 |
|
|
109 |
<5 |
|
|
|
Respiratorisk syncytialt virus |
223 |
<5 |
|
|
174 |
<5 |
|
|
212 |
<5 |
|
|
161 |
<5 |
|
|
|
Humant metapneumovirus |
123 |
<5 |
|
|
106 |
<5 |
|
|
113 |
<5 |
|
|
109 |
<5 |
|
|
|
Rhinovirus |
123 |
6 |
5 % |
|
106 |
5 |
5 % |
|
113 |
7 |
6 % |
|
109 |
7 |
6 % |
|
|
SARS-CoV-2 |
526 |
10 |
2 % |
|
414 |
9 |
2 % |
|
453 |
<5 |
|
|
381 |
<5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ambulante pasientar |
Veke 21-32 |
|
Veke 21-31 |
|
Veke 21-30 |
|
Veke 21-29 |
|
|
Totalt |
Påvist |
|
Totalt |
Påvist |
|
Totalt |
Påvist |
|
Totalt |
Påvist |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bordetella pertussis |
196 |
<5 |
|
|
181 |
<5 |
|
|
161 |
<5 |
|
|
158 |
<5 |
|
|
|
Bordetella parapertussis |
196 |
<5 |
|
|
181 |
<5 |
|
|
161 |
<5 |
|
|
158 |
<5 |
|
|
|
Mycoplasma pneumoniae |
196 |
<5 |
|
|
181 |
<5 |
|
|
161 |
<5 |
|
|
158 |
<5 |
|
|
|
Chlamydia pneumoniae |
196 |
<5 |
|
|
181 |
<5 |
|
|
161 |
<5 |
|
|
158 |
<5 |
|
|
|
Influensavirus A |
217 |
<5 |
|
|
206 |
<5 |
|
|
173 |
<5 |
|
|
163 |
<5 |
|
|
|
Influensavirus B |
217 |
<5 |
|
|
206 |
<5 |
|
|
173 |
<5 |
|
|
163 |
<5 |
|
|
|
Parainfluensavirus 1 |
196 |
<5 |
|
|
181 |
<5 |
|
|
161 |
<5 |
|
|
158 |
<5 |
|
|
|
Parainfluensavirus 2 |
196 |
<5 |
|
|
181 |
<5 |
|
|
161 |
<5 |
|
|
158 |
<5 |
|
|
|
Parainfluensavirus 3 |
196 |
5 |
3 % |
|
181 |
5 |
3 % |
|
161 |
<5 |
|
|
158 |
<5 |
|
|
|
Respiratorisk syncytialt virus |
211 |
<5 |
|
|
195 |
<5 |
|
|
168 |
<5 |
|
|
161 |
<5 |
|
|
|
Humant metapneumovirus |
196 |
<5 |
|
|
181 |
<5 |
|
|
161 |
<5 |
|
|
157 |
<5 |
|
|
|
Rhinovirus |
196 |
32 |
16 % |
|
181 |
27 |
15 % |
|
161 |
23 |
14 % |
|
157 |
27 |
17 % |
|
|
SARS-CoV-2 |
18388 |
647 |
4 % |
|
16389 |
627 |
4 % |
|
12445 |
448 |
4 % |
|
8927 |
216 |
2 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inneliggjande pasientar omfatter fleire
sjukehus i vår region |
|
|
|
|
|
|
|
18.08.2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|